{
    "nct_id": "NCT05115292",
    "official_title": "A First-in-Human, Multicenter, Open-label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma",
    "inclusion_criteria": "1. Male or female ≥ 18 years.\n2. Willing and able to provide signed and dated informed consent prior to any study-related procedures and willing and able to comply with all study procedures.\n3. Histologically or cytologically confirmed advanced solid tumors or lymphoma\n4. Measurable or evaluable disease per RECIST v1.1\n5. ECOG performance status 0 or 1\n6. Life expectancy ≥3 months\n7. Adequate hepatic function\n8. Calculated creatinine clearance (CrCL) > 50 mL/min (Cockroft-Gault Equation)\n9. Adequate Hematological function\n10. Prothrombin time, international normalized ratio or activated partial thromboplastin time < 1.5 × ULN\n11. Recovery, to Grade 0-1, from adverse events related to prior anticancer therapy\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Prior therapy with anti PD-L1/TGFβRⅡ targeting treatment.\n2. Symptomatic primary central nervous system (CNS) tumor of CNS metastases.\n3. Uncontrolled hypertension.\n4. Significant thrombotic or hemorrhagic events.\n5. Prior CAR-T therapy\n6. Severe cardiovascular disease.\n7. Active infection requiring therapy\n8. Active HIV, hepatitis B or hepatitis C virus\n9. Active tuberculosis\n10. Anticancer therapy or radiation therapy within 5 half-lives or 4 weeks (whichever is shorter) prior to study entry\n11. Pregnant or breast-feeding females\n12. Active or history of autoimmune disease or inflammatory disorders",
    "miscellaneous_criteria": ""
}